User: Guest  Login
More Searchfields
Simple search
Title:

RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.

Document type:
Journal Article; Research Support, Non-U.S. Gov't; Journal Article
Author(s):
Fahrig, R; Quietzsch, D; Heinrich, JC; Heinemann, V; Boeck, S; Schmid, RM; Praha, C; Liebert, A; Sonntag, D; Krupitza, G; Hänel, M
Abstract:
RP101 [(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)], which supports apoptosis and prevents the acquisition of chemoresistance, was tested in cultured human pancreatic tumor cells. RP101 downregulated uridine phosphorylase, a marker of poor prognosis, and APEX1, which is involved in DNA repair, and repressed Stat3 and its target vascular endothelial growth factor. Furthermore, RP101 activated antitumor immunity as demonstrated by enhanced cytolytic activity of NK-92 natural killer cells. This was...     »
Journal title abbreviation:
Anticancer Drugs
Year:
2006
Journal volume:
17
Journal issue:
9
Pages contribution:
1045-56
Language:
eng
Fulltext / DOI:
doi:10.1097/01.cad.0000231472.92406.d2
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17001178
Print-ISSN:
0959-4973
TUM Institution:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX